Current Research and Scholarly Interests Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I and II clinical trials of new antibodies to activate the immune system as a cancer therapy. Our current phase I trial uses the Hu5F9-G4 monoclonal antibody discovered at Stanford, to inhibit the CD47 pathway and thus activate macrophages against cancers. Laboratory projects include studies of the multidrug transporter P-glycoprotein, regulation of the MDR1 gene, and the role of beta tubulin gene expression in resistance to taxanes and vinca alkaloids. In addition, we are studying Hu5F9-G4 in mouse models of human ovarian cancers, used as a single agent and in combination with other antibodies and with chemotherapies.